Scott DreesChief Executive Officer
Mr. Drees joined Nuvectra and has served as the company’s CEO since July of 2016. From 2008 until joining Nuvectra, Mr. Drees served as a founding partner of the QiG group and led the neuromodulation incubation team formed by Integer Holdings (formerly Greatbatch, Inc.) that created the Algovita (SCS) and Virtis (SNM) neurostimulation systems. In addition, from 2008 to 2015, Mr. Drees also served as the President and CEO of Neuromodulation Ventures, LLC, a private company focused solely on the neurostimulation industry. Mr. Drees has 37 years of experience in the medical device industry and has spent his last 22 years focused on neuromodulation markets and therapies. He served in executive positions from 1996-2006, as founding Division President and later Executive VP, Worldwide Sales & Marketing, at Advanced Neuromodulation Systems, Inc. (ANSI), a company acquired by St. Jude Medical, Inc., in 2005. Between 1981 and 1996, Mr. Drees held a variety of positions at St. Jude Medical, Boston Scientific, and Johnson and Johnson’s Codman Division. Mr. Drees earned his B.S. Degree from St. Joseph’s University, Philadelphia.
Melissa BeareExecutive Vice President, General Counsel
Melissa Beare joined the Nuvectra organization in 2015 as Vice President, General Counsel and Chief Compliance Officer responsible for all of the company’s legal matters and its compliance program. Ms. Beare has more than 5 years of experience in the medical device industry. Prior to joining Nuvectra, Ms. Beare was Assistant General Counsel at Speed Commerce, Inc. She also spent 5 years as the General Counsel at Peerless Mfg. Co. in Dallas, Texas and over 4 years as Assistant General Counsel at St. Jude Medical’s Neuromodulation Division. She began her career in the corporate practice groups at the firms of Hughes & Luce and Jones Day. Ms. Beare has a B.A. and a J.D. from the University of Texas at Austin.
Walter BergerChief Operating Officer & Chief Financial Officer
Prior to joining Nuvectra, Walter Berger served as Chief Financial Officer of AppDynamics Inc., a venture-backed next generation application intelligence company from October 2013 until March 2015. Prior to that, from 2012 until 2013, Mr. Berger was the Chief Financial Officer of private equity owned SoftLayer, a cloud computing company, which was acquired by IBM. From 2008 until 2012, he served as Chief Financial Officer at Leap Wireless International, Inc. (NASDAQ). Mr. Berger has also served as Executive Vice President and Chief Financial Officer for CBS Radio, Inc. and for Emmis Communications Corporation (NASDAQ). From 1985 to 1999, Mr. Berger held a number of financial and operating management roles in the manufacturing, services, and energy fields. Mr. Berger began his career at Arthur Andersen. He is a Certified Public Accountant and holds a B.A. in Business Administration from the University of Massachusetts, Amherst.
Bernie BosleyExecutive Director, Regulatory & Clinical Affairs
Prior to joining Nuvectra as President, Paul Hanchin served as Executive Vice President for Flowonix Medical, Inc., where he had primary responsibilities for global sales and marketing functions. Before that, he served as the President for Ethos Laboratories. Mr. Hanchin has 30 years of experience in the medical device field, including executive leadership positions at small and large, high-growth companies. He served as Division Vice President for St. Jude Medical from 2005 to 2013, with general management responsibilities for the Neuromodulation and Structural Heart divisions. He has also served in a wide variety of general management, sales, and marketing positions at Boston Scientific, Inc., Cyberonics Inc. and Advanced Neuromodulation Systems, Inc., which was acquired by St. Jude Medical, Inc. Mr. Hanchin has a B.A. in Marketing from Baldwin Wallace University and is a graduate of Kellogg School of Management’s Executive Program.
Chuck HarveyVP, Chief Information Officer
Daryl Kipke, PhDPresident, NeuroNexus
Daryl Kipke joined the Nuvectra organization as part of QiG Group in 2012 through the acquisition of NeuroNexus. Dr. Kipke co-founded NeuroNexus and is responsible for leading the development and commercialization of its advanced neural interface systems for clinical and scientific markets. He has more than 25 years of experience in academia and neuro technology, including founding an earlier company and leading it to a successful exit. He was formerly a professor of Biomedical Engineering at the University of Michigan where he led the Neural Engineering Laboratory and directed the Center for Neural Communication Technology. Dr. Kipke has over 175 scientific publications and holds 30 patents. Dr. Kipke holds B.S., M.S., and Ph.D. degrees in Electrical Engineering and Bioengineering from the University of Michigan.
Jennifer KosharekVice President, Controller and Principal Accounting Officer
Jennifer Kosharek joined Nuvectra in January 2016 as Executive Director, Corporate Controller, and was appointed Vice President, Controller and Principal Accounting Officer, in June 2018. Ms. Kosharek leads the company’s external financial reporting, corporate accounting, corporate internal controls, shared services, payroll, and tax functions. Ms. Kosharek has held various finance and leadership positions and has more than 15 years of audit and accounting experience, including 7 years of public company accounting experience. Prior to joining Nuvectra, Ms. Kosharek was the Corporate Controller and subsequently served as the Chief Financial Officer and Vice President of Finance of Interphase Corporation from 2011 to 2015. Preceding her position at Interphase, Ms. Kosharek served as Senior Accountant – External Reporting and later as Accounting Manager at Sabre Holdings from 2008 to 2011. She began her career at Grant Thornton, LLP. Ms. Kosharek is a Certified Public Accountant and holds a Master’s of Public Accountancy from the University of Wisconsin-Whitewater.
Alan MockVice President, Business Development
Alan Mock joined the Nuvectra organization as part of QiG Group in April 2013 as Vice President of Commercialization and is responsible for developing and executing the commercialization plan for Nuvectra. Mr. Mock has more than 30 years of medical device experience in all aspects of sales and marketing. Prior to Nuvectra, Alan spent 15 years with Advanced Neuromodulation Systems (ANS) and, later, St. Jude Medical (SJM) as VP of Marketing for Chronic Pain Therapies and later as VP of Sales and Marketing for Neuro Therapies. During this time at ANS/SJM, he was responsible for the global commercialization of multiple product lines. Prior to ANS, Mr. Mock was VP of Sales and Marketing for Snowden-Pencer. Mr. Mock has a B.A. from the University of Florida.
Bonnie SchmidtExecutive Director, Human Resources
Bonnie Schmidt joined Nuvectra in 2015 as Director of Human Resources and is responsible for strategic and functional responsibilities across all HR disciplines. Ms. Schmidt has more than 20 years of human resources experience across numerous industries including medical devices, pharmaceutical commercialization, and healthcare analytics. Prior to joining Nuvectra, she served as the Director of HR for Sonexus Health, a Cardinal Health company. Preceding her position at Sonexus Health, Ms. Schmidt served as Senior HR Manager for St. Jude Medical. Ms. Schmidt has an M.B.A. in Healthcare Management from the University of Scranton and a B.A. from the University of Phoenix-Dallas.
Ben TranchinaChief Technology Officer
Ben Tranchina joined Nuvectra in August of 2018. He has more than 25 years of experience in technology business leadership in both early-stage and multi-national commercial companies and holds approximately 30 issued or pending patents relevant to neuromodulation. Prior to joining Nuvectra as Chief Technology Officer, Mr. Tranchina served as the Chief Technology Officer for Neurotechnology Innovations Translator (NIT) LLC, a privately held company in Columbus, Ohio, which develops and commercializes neurotechnology solutions. During his tenure at NIT, Mr. Tranchina also served as CEO for NIT portfolio company Veressa Medical where he led the development of an innovative peripheral nerve stimulation system for the treatment of pelvic floor dysfunction and peripheral pain. Before that, Mr. Tranchina served in various leadership roles and as VP of Research and Development for ten years at St. Jude Medical’s (SJM) Neuromodulation Division and Advanced Neuromodulation Systems, Inc. (ANSI), a company acquired by St. Jude Medical, Inc., in 2005. During his time at SJM, Mr. Tranchina’s teams launched nine first-to-market products, and, as a result, he was awarded SJM’s Neuromodulation Inventor of the Year award. Mr. Tranchina holds a B.S. and a M.S. in Electrical Engineering from the University of Texas at Dallas, specializing in Microelectronic Circuits and Systems.